Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development - PubMed (original) (raw)
Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development
Daniela Milani et al. J Clin Endocrinol Metab. 2004 May.
Abstract
In recent years, a number of investigators have studied the relationship between IGF-I and risk of developing cancer, diabetes or cardiovascular disease. Upper tertile, quartile, and quintile IGF-Is were associated with higher risk of developing cancer, and lowest quartile with cardiac disease and diabetes. As part of a study to correlate serum IGF-Is and growth hormone dynamics in aging, we measured fasting serum IGF-I at baseline and two weeks later in a group of 84 normal volunteers between the ages of 50 and 90 years. Although the correlation between the two IGF-Is was high (r=0.922; p<0.0001) there were substantial differences between the two IGF-I values ranging from -36.25 to +38.24% between individual IGF-I values at the two blood draws and a significant difference between the mean IGF-Is at visits I and 2 (mean 120.28+/-53.5 vs. 114.95+/-50.03; p=0.03). When considered in quartiles, IGF-I changed from one quartile to another in 34/84 (40.5%) of the volunteers. When the group was divided in halves, tertiles,quartiles, or quintiles there was an increasing number of subjects who changed from one subdivision to another as the number of gradations increased. These results suggest that the predictive outcomes of earlier studies that used single IGF-I samples for analysis of risk ratios according to tertiles, quartiles, or quintiles could have been different if a second IGF-I was used to establish the risk ratio. The results also suggest that variability in IGF-I should be taken into account when designing such studies.
Figures
Figure 1
Percent Change of IGF-I from Visit 1 to Visit 2
Figure 2
Subjects who changed quartile from visit 1 (IGF-I_V1) to visit 2 (IGF-I_ V2). Arrows indicate direction of change for each subject. Quartile 1 (Q1) range: 45-92 ng/ml. Quartile 2 (Q2) range: 93-107 ng/ml. Quartile 3 (Q3) range: 108-139 ng/ml. Quartile 4 (Q4) range: 140-351 ng/ml.
Similar articles
- Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Krajcik RA, et al. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12496045 - Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Spitz MR, et al. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1413-8. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433720 Clinical Trial. - Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Chokkalingam AP, et al. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):421-7. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11352850 - Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test.
Svensson J, Johannsson G, Bengtsson BA. Svensson J, et al. Clin Endocrinol (Oxf). 1997 May;46(5):579-86. doi: 10.1046/j.1365-2265.1997.1851001.x. Clin Endocrinol (Oxf). 1997. PMID: 9231054
Cited by
- Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ. Labadzhyan A, et al. Pituitary. 2021 Dec;24(6):943-953. doi: 10.1007/s11102-021-01163-2. Epub 2021 Jun 25. Pituitary. 2021. PMID: 34173129 Free PMC article. Clinical Trial. - Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
Monson KR, Goldberg M, Wu HC, Santella RM, Chung WK, Terry MB. Monson KR, et al. Breast Cancer Res. 2020 Oct 22;22(1):109. doi: 10.1186/s13058-020-01352-0. Breast Cancer Res. 2020. PMID: 33092613 Free PMC article. - Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S. Samson SL, et al. J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3785-97. doi: 10.1210/clinem/dgaa526. J Clin Endocrinol Metab. 2020. PMID: 32882036 Free PMC article. Clinical Trial. - Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.
Cozzi R, Ambrosio MR, Attanasio R, Bozzao A, De Marinis L, De Menis E, Guastamacchia E, Lania A, Lasio G, Logoluso F, Maffei P, Poggi M, Toscano V, Zini M, Chanson P, Katznelson L. Cozzi R, et al. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1133-1143. doi: 10.2174/1871530320666200127103320. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31985386 Free PMC article. Review. - Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays.
Chanson P, Arnoux A, Mavromati M, Brailly-Tabard S, Massart C, Young J, Piketty ML, Souberbielle JC; VARIETE Investigators. Chanson P, et al. J Clin Endocrinol Metab. 2016 Sep;101(9):3450-8. doi: 10.1210/jc.2016-1257. Epub 2016 May 11. J Clin Endocrinol Metab. 2016. PMID: 27167056 Free PMC article.
References
- Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science. 1998;279:563–566. - PubMed
- Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393–1396. - PubMed
- Janssen JA, Lamberts SWJ. Insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;352:490. - PubMed
- Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer [In Process Citation]. Journal of Clinical Endocrinology and Metabolism. 2000;85:4258–4265. - PubMed
- Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer [In Process Citation]. International Journal of Cancer. 2000;88:828–832. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- M01 RR000096/RR/NCRR NIH HHS/United States
- M01 RR000096-38/RR/NCRR NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P30-AG 08051/AG/NIA NIH HHS/United States
- M01RR00096/RR/NCRR NIH HHS/United States
- P30 AG008051-10/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials